CN107973727B - 间二取代苯酚化合物及其制备方法与抗结核菌应用 - Google Patents

间二取代苯酚化合物及其制备方法与抗结核菌应用 Download PDF

Info

Publication number
CN107973727B
CN107973727B CN201711310722.7A CN201711310722A CN107973727B CN 107973727 B CN107973727 B CN 107973727B CN 201711310722 A CN201711310722 A CN 201711310722A CN 107973727 B CN107973727 B CN 107973727B
Authority
CN
China
Prior art keywords
benzyl
hydroxyphenyl
phenol compound
disubstituted phenol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201711310722.7A
Other languages
English (en)
Other versions
CN107973727A (zh
Inventor
鄢明
张天宇
张妞妞
刘志永
钱露
唐运祥
程亚娟
张学景
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Institute of Biomedicine and Health of CAS
Sun Yat Sen University
Original Assignee
Guangzhou Institute of Biomedicine and Health of CAS
Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Institute of Biomedicine and Health of CAS, Sun Yat Sen University filed Critical Guangzhou Institute of Biomedicine and Health of CAS
Priority to CN201711310722.7A priority Critical patent/CN107973727B/zh
Publication of CN107973727A publication Critical patent/CN107973727A/zh
Application granted granted Critical
Publication of CN107973727B publication Critical patent/CN107973727B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/29Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/26Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/75Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/80Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/32Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/38Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/061,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明提供了一类通式为(Ⅰ)的间二取代苯酚化合物、其制备方法与应用。所述的间二取代苯酚化合物具有新的抗结核菌药母核结构和优秀的抗结核菌活性,特别是对耐药的变异结核菌株也具有很强的抑制活性。本发明还提供了所述的间二取代苯酚化合物的制备方法,该制备方法的原料廉价易得,无需使用高毒性和高污染试剂,反应步骤简单,可实现工业化生产;具有良好的药用前景。

Description

间二取代苯酚化合物及其制备方法与抗结核菌应用
技术领域
本发明属于药物化学领域,特别涉及一类间二取代苯酚化合物及其制备方法与抗结核菌应用。
背景技术
结核病是由结核分枝杆菌引起的一种慢性致死性疾病,其每年致死人数已超过艾滋病,严重危害人类健康。目前,由于多药耐药和广泛耐药变异结核菌的出现,以及与HIV共同感染的结核病人的出现,大大增加了治疗肺结核的难度。临床上对一线抗结核药物异烟肼、利福平、吡嗪酰胺和链霉素产生耐药的病人比例已经接近15%,而二线药物由于副作用较大,并不适合长期用药。
因此,发现新结构、高选择性、与现有一线药物不产生交叉耐药性的抗结核新药物具有十分重要的临床应用价值。
发明内容
本发明的首要目的在于克服现有技术的缺点与不足,提供一类间二取代苯酚化合物,所述的间二取代苯酚化合物具有抗结核菌活性。
本发明的第二目的在于提供一种药物组合物,包括所述的间二取代苯酚化合物或其药学可接受的盐、立体异构体或溶剂化物,以及任选的药学可接受的辅料、载体或赋形剂。
本发明的第三目的在于提供所述的间二取代苯酚化合物的制备方法。
本发明的第四目的在于提供所述的间二取代苯酚化合物在制备预防和/或治疗结核病的药物中的应用。
本发明的第五目的在于提供所述的间二取代苯酚化合物在制备预防和/或治疗分枝杆菌感染引起的疾病的药物中的应用。
本发明的目的通过下述技术方案实现:
通式Ⅰ所示的化合物,或其药学可接受的盐、立体异构体或溶剂化物,
Figure BDA0001502931470000021
其中,R1为甲基、乙基、乙烯基、C3~C8烷基及环烷基、甲氧基、苯基、萘基、噻吩基、呋喃基、吡啶基、嘧啶基、喹啉基、噻唑基、噻二唑基、苯氧基、苄氧基、乙氧基、C3~C8烷基氧基及环烷基氧基、四氢吡喃基、四氢呋喃基;其中在苯基、萘基、噻吩基、呋喃基、吡啶基、嘧啶基、喹啉基、噻唑基、苯氧基、苄氧基的芳香环上还可以有单取代或者多取代基,取代基可以是甲基、乙基、C3~C6烷基及环烷基、氟、氯、溴、甲氧基、硝基、三氟甲基、腈基、羟基;
R2为无取代、单取代或多取代的苯基、噻吩基、呋喃基、吡啶基、吡嗪基、嘧啶基、噻唑基、吡唑基、三氮唑基,取代基可以是甲基、氟、氯、溴、甲氧基、三氟甲基、腈基;
X为CH2、O、S、NH和NCH3
所述的R1优选为C5~C8环烷基、苯基、苯基氧基、C5~C8环烷基氧基,其中在苯基、苯基氧基的苯环上还可以有单取代或者多取代,取代基可以是甲基、氯、氟。
所述的R2优选为苯基。
所述的X优选为CH2或NCH3
进一步优选为以下化合物:
3-苄基-5-羟基苯基-氨基甲酸-4,4-二甲基环己酯;
N-(3-苄基-5-羟基苯基)-4,4-二甲基-环己烷甲酰胺;
N-(3-苄基-5-羟基苯基)-4-甲基苯甲酰胺;
N-(3-羟基-5-(甲基苯胺基)苯基)-环己烷甲酰胺;
N-(3-苄基-5-羟基苯基)环己基甲酰胺;
N-(3-苄基-5-羟基苯基)-2-(4,4-二甲基环己基)乙酰胺;
N-(3-苄基-5-羟基苯基)苯甲酰胺;
N-(3-苄基-5-羟基苯基)-2-氯苯甲酰胺;
N-(3-苄基-5-羟基苯基)-2,4-二氯苯甲酰胺;
N-(3-苄基-5-羟基苯基)-2-氯烟酰胺;
N-(3-苄基-5-羟基苯基)噻吩-2-甲酰胺;
3-苄基-5-羟基苯基-氨基甲酸乙酯;
N-(3-羟基-5-苯氧基苯基)-苯甲酰胺;
N-(3-羟基-5-(甲基苯胺基)苯基)-苯甲酰胺;
N-(3-羟基-5-(甲基-2-吡啶基胺基)苯基)-苯甲酰胺;
N-(3-羟基-5-(甲基-2-吡嗪基胺基)苯基)-苯甲酰胺;
N-(3-苄基-5-羟基苯基)-2-苯乙酰胺;
N-(3-苄基-5-羟基苯基)-4,4-二氟环己基甲酰胺;
N-(3-苄基-5-羟基苯基)四氢吡喃-4-甲酰胺。
一种药物组合物,包括所述的间二取代苯酚化合物或其药学可接受的盐、立体异构体或溶剂化物,以及任选的药学可接受的辅料、载体或赋形剂。
所述的间二取代苯酚化合物的制备方法,包括如下步骤:
当X为CH2时,采用3-硝基-5-甲氧基苯甲酸为原料,经过还原成醇、傅克烷基化、脱甲基、硝基还原和酰化反应制备得到所述的间二取代苯酚化合物;
具体地,包括如下步骤:
(1)以3-硝基-5-甲氧基苯甲酸为原料,经还原后得到3-硝基-5-甲氧基苄醇;
(2)3-硝基-5-甲氧基苄醇与芳香族化合物R2H发生傅克烷基化反应,得到化合物A;
(3)化合物A发生脱甲基反应,得到化合物B;
(4)还原化合物B中的硝基,得到化合物C;
(5)化合物C与R1COCl、或(R1CO)2O、或R1COOH发生反应,即得所述的间二取代苯酚化合物D。
合成路线如下:
Figure BDA0001502931470000041
所述的合成路线中的反应试剂和条件优选如下:
a.NaBH4、BF3.OEt2、THF或LiAlH4、THF;
b.R2H、AlCl3
c.BBr3、CH2Cl2或NaH、EtSH、DMF;
d.还原剂优选为Pd/C催化加氢,或铁粉,或锌粉中的至少一种;进一步优选为10%Pd/C、H2,或铁粉、醋酸/甲醇/水,或锌粉、醋酸/甲醇/水;
e.R1COCl、Et3N、CH2Cl2,或(R1CO)2、Et3N、CH2Cl2,或R1COOH、亚磷酸三苯酯、甲苯。
当X为O、S、NH、NCH3时,采用3-溴-5-硝基苯甲醚为原料,经过硝基还原、酰化、偶联、脱甲基反应制备得到所述的间二取代苯酚化合物;
具体地,包括如下步骤:
(1)3-溴-5-硝基苯甲醚还原得到3-溴-5-甲氧基苯胺;
(2)3-溴-5-甲氧基苯胺与R1COCl,或(R1CO)2,或R1COOH发生酰化反应,得到化合物E;
(3)化合物E与R2XH发生偶联反应,得到化合物F;
(4)化合物F发生脱甲基反应,即得所述的间二取代苯酚化合物G。
合成路线如下:
Figure BDA0001502931470000042
所述的合成路线中的反应试剂和条件优选如下:
a.铁粉或锌粉、醋酸/甲醇/水;
b.R1COCl、Et3N、CH2Cl2,或(R1CO)2、Et3N、CH2Cl2,或R1COOH、亚磷酸三苯酯、甲苯;
c.R2XH、CuI、K3PO4、DMSO;
d.BBr3、CH2Cl2或NaH、EtSH、DMF。
所述的间二取代苯酚化合物或所述的药物组合物在制备预防和/或治疗结核病的药物中的应用。
所述的结核病包括肺结核或肺外结核。
所述的结核病包括活动性结核病、单耐药结核病、多耐药结核病或广泛耐多药结核病。
所述的间二取代苯酚化合物或所述的药物组合物在制备预防和/或治疗分枝杆菌感染引起的疾病的药物中的应用。
所述的分枝杆菌为结核分枝杆菌;进一步优选为结核分枝杆菌H37Rv,或对异烟肼和利福平耐药的临床分离结核分枝杆菌P103、R7、P91。
本发明相对于现有技术具有如下的优点及效果:
1.本发明提供了一类间二取代苯酚化合物,具有新的抗结核菌药母核结构和优秀的抗结核菌活性,特别是对耐药的变异结核菌株也具有很强的抑制活性。
2.本发明提供了上述的间二取代苯酚化合物的制备方法,采用3-硝基-5-甲氧基苯甲酸为原料,经过还原成醇、傅克烷基化、脱甲基、硝基还原和酰化反应制备得到所述的间二取代苯酚化合物;或者采用3-溴-5-硝基苯甲醚为原料,经过硝基还原、酰化、偶联、脱甲基反应制备得到。上述的合成路线原料廉价易得,不使用高毒性和高污染试剂,反应步骤简单,可实现工业化生产。
具体实施方式
下面结合实施例对本发明作进一步详细的描述,但本发明的实施方式不限于此。
实施例中反应所用的原料可以由本领域技术人员根据已有知识制备得到,或可以通过商业途径购得。
实施例1合成N-(3-苄基-5-羟基苯基)-2-苯乙酰胺
Figure BDA0001502931470000061
在100mL两口瓶中,在氩气保护下加入硼氢化钠(1.6g,42mmol)和重蒸的四氢呋喃(20mL),在0℃下缓慢加入3-硝基-5-甲氧基苯甲酸(3.94g,20mmol),再加入三氟化硼乙醚溶液6.7mL。在室温下反应4h,反应液在冰浴冷却下用稀盐酸淬灭,然后用二氯甲烷(30mL×2)萃取。萃取液在减压下除去溶剂得到粗产物3-硝基-5-甲氧基苄醇3.6g,直接用于下一步反应。
在100mL圆底烧瓶中,加入无水三氯化铝(5.58g,42mmol)、无水苯20mL和二氯甲烷10mL,在冰浴条件下缓慢加入3-硝基-5-甲氧基苄醇(3.6g,20mmol),然后于80℃条件下回流5h。反应液冷却后倒入冰水中,用乙酸乙酯(30mL×2)萃取。萃取液在减压下除去溶剂得到粗产物,用硅胶层析纯化(石油醚/乙酸乙酯梯度洗脱)得到黄色固体即1-苄基-3-硝基-5-甲氧基苯2.0g,产率41%。
在200mL两口瓶中,加入1-苄基-3-硝基-5-甲氧基苯(2.0g,8.2mmol)和重蒸的二氯甲烷50mL,在-78℃下缓慢加入三溴化硼二氯甲烷溶液42mL(1mol/L),然后在0℃条件下反应12h。反应液用饱和碳酸氢钠溶液淬灭,然后用二氯甲烷(30mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶层析纯化(石油醚/乙酸乙酯梯度洗脱)得到黄色固体即1-苄基-3-硝基苯酚577mg,产率30%。
在100mL两口瓶中,加入1-苄基-3-硝基苯酚(577mg,2.5mmol)、20mL甲醇/二氯甲烷(V/V=1/1)混合溶剂和10%Pd/C(60mg),在一个大气压的氢气下反应2h。将反应液过滤,滤液在减压下除去溶剂得到灰色固体即1-苄基-3-氨基苯酚400mg,产率80%。
在25mL圆底烧瓶中,在冰浴条件下加入1-苄基-3-氨基苯酚(99.5mg,0.5mmol)、苯乙酰氯(73μL,0.55mmol)、三乙胺(76μL,0.55mmol)和重蒸的四氢呋喃2mL,在室温下反应12h。反应液用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶层析纯化(石油醚/乙酸乙酯梯度洗脱)得到红色固体即N-(3-苄基-5-羟基苯基)-2-苯乙酰胺113mg,产率71%。
1H NMR(400MHz,DMSO)δ9.94(s,1H),9.27(s,1H),7.32–7.17(m,10H),7.05(s,1H),6.81(s,1H),6.31(s,1H),3.76(s,2H),3.58(s,2H).13C NMR(100MHz,DMSO)δ169.36,158.03,143.08,141.52,140.60,136.55(s),129.50,129.18,128.82,128.72,126.93,126.40,111.37,110.84,104.63,43.84,41.75.高分辨质谱(ESI)C21H19NO2[M+H]+:理论值:318.1489,实测值:318.1478。
实施例2合成N-(3-苄基-5-羟基苯基)环己基甲酰胺
Figure BDA0001502931470000071
1-苄基-3-氨基苯酚的合成参见实施例1。在50mL圆底烧瓶中,冰浴冷却下加入1-苄基-3-氨基苯酚(99.5mg,0.5mmol)、环己烷甲酰氯(74μL,0.55mmol)、三乙胺(76μL,0.55mmol)和重蒸的四氢呋喃2mL,在室温下反应12h,反应液用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶柱层析纯化(石油醚/乙酸乙酯梯度洗脱)得到白色固体即N-(3-苄基-5-羟基苯基)环己烷甲酰胺75mg,产率49%。
1H NMR(400MHz,DMSO)δ9.59(s,1H),9.24(s,1H),7.28(m,2H),7.19(m,3H),7.04(m,1H),6.84(m,1H),6.28(m,1H),3.77(s,2H),2.27(t,J=11.4Hz,1H),1.73(d,J=9.2Hz,4H),1.63(d,J=9.6Hz,1H),1.37(m,2H),1.30–1.14(m,3H).13C NMR(101MHz,DMSO)δ174.62,157.96,142.93,141.62,140.91,129.18,128.82,126.39,111.02,110.82,104.55,45.31,41.80,29.61,25.88,25.71。高分辨质谱(ESI)C20H24NO2[M+H]+:理论值:310.1802,实测值:310.1800。
实施例3合成N-(3-苄基-5-羟基苯基)-2-(4,4-二甲基环己基)乙酰胺
Figure BDA0001502931470000081
1-苄基-3-氨基苯酚的合成参见实施例1。在25mL圆底烧瓶中,加入1-苄基-3-氨基苯酚(160mg,0.8mmol)、2-(4,4-二甲基环己基)乙酸(204mg,1.2mmol)、亚磷酸三苯酯(314μL,1.2mmol)和重蒸的甲苯5mL,在110℃反应12h。反应液减压除去溶剂,残余物用硅胶柱层析纯化(石油醚/二氯甲烷梯度洗脱),得到白色固体即N-(3-苄基-5-羟基苯基)-2-(4,4-二甲基环己烷)乙酰胺127mg,产率45%。
1H NMR(400MHz,DMSO)δ9.60(s,1H),9.21(s,1H),7.28(m,2H),7.18(m,3H),7.06(m,1H),6.79(m,1H),6.28(m,1H),3.78(s,2H),2.15(d,J=7.1Hz,2H),1.64(m,1H),1.49(m,2H),1.33(m,2H),1.19–1.10(m,4H),0.87(s,3H),0.86(s,3H).13C NMR(101MHz,DMSO)δ170.89,157.99,142.94,141.58,140.70,129.19,128.82,126.40,111.12,110.82,104.65,44.32,41.78,38.86,35.18,32.83,30.07,28.67,24.97.高分辨质谱(ESI)C23H29NO2[M+H]+:理论值:352.2271,实测值:352.2273.
实施例4合成N-(3-苄基-5-羟基苯基)-4,4-二氟环己基甲酰胺
Figure BDA0001502931470000082
1-苄基-3-氨基苯酚的合成参见实施例1。在25mL圆底烧瓶中,加入1-苄基-3-氨基苯酚(160mg,0.8mmol)、4,4-二氟环己烷甲酸(197mg,1.2mmol)、亚磷酸三苯酯(314μL,1.2mmol)和重蒸的甲苯5mL,在110℃反应12h。反应液减压除去溶剂,残余物用硅胶柱层析纯化(石油醚/二氯甲烷梯度洗脱),得到黄色固体即N-(3-苄基-5-羟基苯基)-4,4-二氟环己烷甲酰胺126mg,产率37%。
1H NMR(400MHz,DMSO)δ9.75(s,1H),9.30(s,1H),7.28(m,2H),7.24–7.15(m,3H),7.03(m,1H),6.83(m,1H),6.30(m,1H),3.78(s,2H),2.42(t,J=10.6Hz,1H),2.08(d,J=8.7Hz,2H),1.86(d,J=10.6Hz,3H),1.75(m,1H),1.65(m,2H).13C NMR(101MHz,DMSO)δ173.17,157.99,143.04,141.58,140.64,129.19,128.84,126.41,124.13(t,1J=239Hz),111.25,110.85,104.62,42.41,41.77,32.72(t,2J=23Hz),26.08,25.99.高分辨质谱(ESI)C20H21NO2F2[M+H]+:理论值:346.1613,实测值:346.1604.
实施例5合成N-(3-苄基-5-羟基苯基)四氢吡喃-4-甲酰胺
Figure BDA0001502931470000091
1-苄基-3-氨基苯酚的合成参见实施例1。在25mL圆底烧瓶中,在冰浴冷却下加入1-苄基-3-氨基苯酚(159mg,0.8mmol)、四氢吡喃-4-甲酰氯(109μL,0.88mmol)、三乙胺(111μL,0.88mmol)和重蒸的四氢呋喃2mL,在室温下反应12h。反应液用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶柱层析纯化(石油醚/乙酸乙酯梯度洗脱),得到白色固体即N-(3-苄基-5-羟基苯基)四氢吡喃-4-甲酰胺197mg,产率63%。
1H NMR(400MHz,MeOD)δ7.30–7.21(m,1H),7.16(m,1H),7.02(m,1H),6.79(m,1H),6.38(m,1H),3.98(dd,J=11.4,2.6Hz,2H),3.84(s,2H),3.45(td,J=11.7,2.1Hz,2H),2.57(tt,J=11.4,4.0Hz,1H),1.89–1.67(m,4H).13C NMR(101MHz,DMSO)δ173.29,157.98,142.99,141.58,140.73,129.19,128.83,126.40,111.20,110.91,104.66,66.87,42.19,41.79,29.33.高分辨质谱(ESI)C19H21NO3[M+H]+:理论值:312.1594,实测值:312.1602。
实施例6合成N-(3-苄基-5-羟基苯基)苯甲酰胺
Figure BDA0001502931470000101
1-苄基-3-氨基苯酚的合成参见实施例1。在25mL圆底烧瓶中,在冰浴冷却下加入1-苄基-3-氨基苯酚(99mg,0.5mmol)、苯甲酰氯(63μL,0.55mmol)、三乙胺(76μL,0.55mmol)和重蒸的四氢呋喃2mL,在室温下反应12h。反应液用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶柱层析纯化(石油醚/乙酸乙酯梯度洗脱),得到白色固体即N-(3-苄基-5-羟基苯基)苯甲酰胺79mg,产率52%。
1H NMR(400MHz,DMSO)δ10.02(s,1H),9.29(s,1H),7.94–7.88(m,1H),7.59–7.53(m,1H),7.50(m,1H),7.29(m,1H),7.20(m,2H),7.06(m,1H),6.37(m,1H),3.83(s,1H).13CNMR(101MHz,DMSO)δ157.82,155.56,142.49,141.80,141.74,129.16,128.79,126.35,111.40,110.08,105.09,66.48,44.68,41.89.高分辨质谱(ESI)C20H18NO2[M+H]+:理论值:304.1332,实测值:304.1324。
实施例7N-(3-苄基-5-羟基苯基)-4-甲基苯甲酰胺
Figure BDA0001502931470000102
1-苄基-3-氨基苯酚的合成参见实施例1。在25mL圆底烧瓶中,在冰浴冷却下加入1-苄基-3-氨基苯酚(99.5mg,0.5mmol)、对甲基苯甲酰氯(73μL,0.55mmol)、三乙胺(76μL,0.55mmol)和重蒸的四氢呋喃2mL,在室温下反应12h。反应液用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶柱层析纯化(石油醚/乙酸乙酯梯度洗脱),得到淡红色固体即N-(3-苄基-5-羟基苯基)-4-甲基苯甲酰胺101mg,产率64%。
1H NMR(400MHz,DMSO)δ9.96(s,1H),9.32(s,1H),7.83(d,J=8.1Hz,2H),7.30(t,J=7.7Hz,4H),7.20(m,4H),7.05(s,1H),6.36(s,1H),3.82(s,2H),2.37(s,3H).13C NMR(101MHz,DMSO)δ165.69,157.93,142.89,141.89,141.63,140.66,132.66,129.29,129.20,128.85,128.14,126.42,112.10,111.70,105.80,41.85,21.46.高分辨质谱(ESI)C21H19NO2[M+H]+:理论值:318.1489,实测值:318.1488。
实施例8合成N-(3-苄基-5-羟基苯基)-3-羟基苯甲酰胺
Figure BDA0001502931470000111
1-苄基-3-氨基苯酚的合成参见实施例1。在25mL圆底烧瓶中,加入1-苄基-3-氨基苯酚(99.5mg,0.5mmol)、间羟基苯甲酸(104mg,0.75mmol)、亚磷酸三苯酯(196.55μL,0.75mmol,)和重蒸的甲苯5mL,在110℃反应12h。反应液减压除去溶剂,残余物用硅胶柱层析纯化(石油醚/二氯甲烷梯度洗脱),得到白色固体即N-(3-苄基-5-羟基苯基)-3-羟基苯甲酰胺99mg,产率62%。
1H NMR(400MHz,DMSO)δ9.95(s,1H),9.68(s,1H),9.29(s,1H),7.37–7.25(m,5H),7.23(s,1H),7.22–7.16(m,3H),7.06(m,1H),6.95(dd,J=7.3,1.8Hz,1H),6.36(s,1H),3.82(s,2H).13C NMR(101MHz,DMSO)δ165.93,157.92,157.76,142.87,141.61,140.62,137.05,129.78,129.19,128.84,126.41,118.82,118.63,115.01,112.12,111.74,105.82,41.85;高分辨质谱(ESI)C20H17NO3[M+H]+:理论值:320.1281,实测值:320.1277。
实施例9合成N-(3-苄基-5-羟基苯基)-2-氯苯甲酰胺
Figure BDA0001502931470000112
1-苄基-3-氨基苯酚的合成参见实施例1。在25mL圆底烧瓶中,在冰浴冷却下加入1-苄基-3-氨基苯酚(160mg,0.8mmol)、2-氯苯甲酰氯(101μL,0.88mmol)、三乙胺(110μL,0.88mmol)和重蒸的四氢呋喃5mL,在室温下反应12h。反应液用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶柱层析纯化(石油醚/乙酸乙酯梯度洗脱),得到白色固体即N-(3-苄基-5-羟基苯基)-2-氯苯甲酰胺140mg,产率52%。
1H NMR(400MHz,DMSO)δ10.29(s,1H),9.34(s,1H),7.57–7.45(m,3H),7.42(m,1H),7.29(m,2H),7.19(m,3H),7.15(m,1H),6.98(m,1H),6.98(m,1H),6.37(m,1H),3.82(s,1H).13C NMR(101MHz,DMSO)δ163.87,158.12,150.82,146.89,143.35,141.46,140.08,138.59,133.79,129.23,128.87,126.46,123.57,112.20,111.27,105.05,41.72;高分辨质谱(ESI)C20H17NO2Cl[M+H]+:理论值:338.0942,实测值:338.0942。
实施例10合成N-(3-苄基-5-羟基苯基)-3,5-双(三氟甲基)苯甲酰胺
Figure BDA0001502931470000121
1-苄基-3-氨基苯酚的合成参见实施例1。在25mL圆底烧瓶中,在冰浴冷却下加入1-苄基-3-氨基苯酚(160mg,0.8mmol)、3,5-双三氟甲基苯甲酰氯(159μL,0.88mmol)、三乙胺(110μL,0.88mmol)和重蒸的四氢呋喃5mL,在室温下反应12h。反应液用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶柱层析纯化(石油醚/乙酸乙酯梯度洗脱),得到白色固体即N-(3-苄基-5-羟基苯基)-3,5-双(三氟甲基)苯甲酰胺168mg,产率48%。
1H NMR(400MHz,DMSO)δ10.48(s,1H),9.46(s,1H),8.58(s,1H),8.34(s,1H),7.30(m,1H),7.21(m,4H),7.02(s,1H),6.45(s,1H),3.86(s,1H).13C NMR(101MHz,DMSO)δ162.82,158.05,143.16,141.51,139.89,137.69,130.86(q,2J=33.4Hz),129.21,129.01(q,4J=1Hz),128.88,126.47,125.44(q,1J=272Hz),123.60(q,1J=272Hz),112.50,112.26,106.08,41.76;高分辨质谱(ESI)C22H16NO2F6[M+H]+:理论值:440.1080,实测值:440.1092。
实施例11合成N-(3-苄基-5-羟基苯基)-2,4-二氯苯甲酰胺
Figure BDA0001502931470000131
1-苄基-3-氨基苯酚的合成参加实施例1。在25mL圆底烧瓶中,在冰浴冷却下加入1-苄基-3-氨基苯酚(160mg,0.8mmol)、2,4-二氯苯甲酰氯(123μL,0.88mmol)、三乙胺(110μL,0.88mmol)和重蒸的四氢呋喃5mL,在室温下反应12h。反应液用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶柱层析纯化(石油醚/乙酸乙酯梯度洗脱),得到白色固体即N-(3-苄基-5-羟基苯基)-2,4-二氯苯甲酰胺205mg,产率55%。
1H NMR(400MHz,MeOD)δ7.55(d,J=1.9Hz,1H),7.49(d,J=8.2Hz,1H),7.41(dd,J=8.2,1.9Hz,1H),7.29–7.22(m,2H),7.22–7.12(m,5H),6.92(s,1H),3.87(s,2H).13C NMR(100MHz,MeOD)δ165.70,157.48,143.41,140.91,139.02135.95,135.26,131.76,129.69,129.37,128.57,128.08,127.14,125.75,112.12,111.96,105.11,41.43.高分辨质谱(ESI)C20H15NO2Cl2[M+H]+:理论值:372.0553,实测值:372.0561。
实施例12合成N-(3-苄基-5-羟基苯基)-2-氯烟酰胺
Figure BDA0001502931470000132
1-苄基-3-氨基苯酚的合成参见实施例1。在25mL圆底烧瓶中,在冰浴冷却下加入1-苄基-3-氨基苯酚(160mg,0.8mmol)、2-氯烟酰氯(154mg,0.88mmol)、三乙胺(110μL,0.88mmol)和重蒸的四氢呋喃5mL,在室温下反应12h。反应液用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶柱层析纯化(石油醚/乙酸乙酯梯度洗脱),得到白色固体即N-(3-苄基-5-羟基苯基)-2-氯烟酰胺129mg,产率48%。
1H NMR(400MHz,DMSO)δ:10.42(s,1H),9.39(s,1H),8.51(d,J=4.7Hz,1H),8.02(d,J=7.4Hz,1H),7.54(dd,J=7.3,4.9Hz,1H),7.30(m,1H),7.21(m,1H),7.14(s,1H),6.94(s,1H),6.40(s,1H),3.84(s,1H).13C NMR(101MHz,DMSO)δ163.87,158.12,150.82,146.89,143.35,141.46,140.08,138.59,133.79,129.23,128.87,126.46,123.57,112.20,111.27,105.05,41.72;高分辨质谱(ESI)C19H16N2O2Cl[M+H]+:理论值:339.0895,实测值:339.0896。
实施例13合成N-(3-苄基-5-羟基苯基)噻吩-2-甲酰胺
Figure BDA0001502931470000141
1-苄基-3-氨基苯酚的合成参见实施例1。在25mL圆底烧瓶中,在冰浴冷却下加入1-苄基-3-氨基苯酚(99mg,0.5mmol)、2-噻吩甲酰氯(58.8μL,0.55mmol)、三乙胺(76.24μL,0.55mmol)和重蒸的四氢呋喃5mL,在室温下反应12h。反应液用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶柱层析纯化(石油醚/乙酸乙酯梯度洗脱),得到白色固体即N-(3-苄基-5-羟基苯基)噻吩-2-甲酰胺94mg,产率61%。
1H NMR(400MHz,DMSO)δ10.01(s,1H),9.34(s,1H),7.99(d,J=3.3Hz,1H),7.82(d,J=4.8Hz,1H),7.36–7.25(m,2H),7.20(m,4H),7.16(s,1H),6.99(s,1H),6.38(s,1H),3.83(s,2H).13C NMR(101MHz,DMSO)δ160.21,157.99,143.02,141.56,140.74,140.12,132.15,129.42,129.20,128.86,128.45,126.44,112.10,111.93,105.87,41.81.高分辨质谱(ESI)C18H15NO2S[M+H]+:理论值:310.0896,实测值:310.0892。
实施例14合成N-(3-苄基-5-羟基苯基)-4-甲基-1,2,3-噻二唑-5-甲酰胺
Figure BDA0001502931470000151
1-苄基-3-氨基苯酚的合成参见实施例1。在25mL圆底烧瓶中,加入1-苄基-3-氨基苯酚(99mg,0.5mmol)、4-甲基-1,2,3-噻二唑-5-羧酸(108mg,0.75mmol)、亚磷酸三苯酯(197μL,0.75mmol)和重蒸的甲苯5mL,在110℃反应12h。反应液减压除去溶剂,残余物用硅胶柱层析纯化(石油醚/二氯甲烷梯度洗脱),得到黄色固体即N-(3-苄基-5-羟基苯基)-4-甲基-1,2,3-噻二唑-5-甲酰胺72mg,产率44%。
1H NMR(400MHz,DMSO)δ10.52(s,1H),9.43(s,1H),7.29(m,2H),7.22(m,3H),7.11(s,1H),6.93(s,1H),6.43(s,1H),3.84(s,2H),2.78(s,3H).13C NMR(101MHz,MeOD)δ159.28,158.18,157.64,144.18,143.49,140.84,138.69,128.58,128.07,125.75,112.49,112.09,105.40,41.40,12.01.高分辨质谱(ESI)C17H15N3O2S[M+H]+:理论值:326.0958,实测值:326.0956。
实施例15合成3-苄基-5-羟基苯基-氨基甲酸-4,4-二甲基环己酯
Figure BDA0001502931470000152
1-苄基-3-氨基苯酚的合成参见实施例1。在50mL圆底烧瓶中,在冰浴冷却下加入1-苄基-3-氨基苯酚(160mg,0.8mmol)、氯甲酸4,4-二甲基环己酯(167mg,0.88mmol)、三乙胺(110μL,0.88mmol)和重蒸的四氢呋喃20mL,在室温下反应12h。反应液用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶柱层析纯化(石油醚/乙酸乙酯梯度洗脱),得到白色固体即3-苄基-5-羟基苯基-氨基甲酸-4,4-二甲基环己酯129mg,产率46%。
1H NMR(400MHz,DMSO)δ9.34(s,1H),9.23(s,1H),7.28(t,J=7.4Hz,2H),7.22–7.14(m,3H),6.80(d,J=10.9Hz,2H),6.23(s,1H),4.68–4.49(m,1H),3.76(s,2H),1.84–1.67(m,2H),1.59–1.47(m,2H),1.47–1.38(m,2H),1.32–1.19(m,2H),0.92(s,3H),0.91(s,3H).13C NMR(101MHz,DMSO)δ157.98,153.44,142.91,141.59,140.74,129.14,128.79,126.37,110.45,110.11,103.86,72.42,41.85,36.27,29.75,27.67.高分辨质谱(ESI)C22H27NO3[M+Na]+:理论值:376.1183,实测值:376.1873。
实施例16合成3-苄基-5-羟基苯基-氨基甲酸苄酯
Figure BDA0001502931470000161
1-苄基-3-氨基苯酚的合成参见实施例1。在50mL圆底烧瓶中,在冰浴冷却下加入1-苄基-3-氨基苯酚(160mg,0.8mmol)、氯甲酸苄酯(149mg,0.88mmol)、三乙胺(110μL,0.88mmol)和重蒸的四氢呋喃20mL,在室温下反应12h。反应液用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶柱层析纯化(石油醚/乙酸乙酯梯度洗脱),得到白色固体即3-苄基-5-羟基苯基-氨基甲酸苄酯114mg,产率43%。
1H NMR(400MHz,DMSO)δ9.57(s,1H),9.26(s,1H),7.43–7.32(m,2H),7.31–7.24(m,1H),7.22–7.14(m,1H),6.83(s,1H),6.78(s,1H),6.24(s,1H),5.11(s,1H),3.77(s,1H).13C NMR(101MHz,DMSO)δ158.10,153.80,143.19,141.71,140.52,137.20,129.15,128.89,128.82,128.45,126.60,126.39,110.68,110.12,103.77,66.17,41.81.高分辨质谱(ESI)C21H19NO3[M+Na]+:理论值:356.1257,实测值:356.1257。
实施例17合成3-苄基-5-羟基苯基-氨基甲酸乙酯
Figure BDA0001502931470000171
1-苄基-3-氨基苯酚的合成参见实施例1。在50mL圆底烧瓶中,在冰浴冷却下加入1-苄基-3-氨基苯酚(160mg,0.8mmol)、氯甲酸乙酯(94mg,0.88mmol)、三乙胺(110μL,0.88mmol)和重蒸的四氢呋喃20mL,在室温下反应12h。反应液用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶柱层析纯化(石油醚/乙酸乙酯梯度洗脱),得到白色固体即3-苄基-5-羟基苯基-氨基甲酸乙酯104mg,产率48%。
1H NMR(400MHz,DMSO)δ9.40(s,1H),9.23(s,1H),7.28(t,J=7.4Hz,1H),7.18(d,J=7.7Hz,1H),6.79(d,J=19.2Hz,1H),6.22(s,1H),4.08(q,J=7.0Hz,1H),3.76(s,1H),1.21(t,J=7.2Hz,2H).13C NMR(101MHz,DMSO)δ158.09,153.89,143.02,141.57,140.64,129.14,128.81,126.38,110.52,110.12,103.76,60.43,41.81,14.99.高分辨质谱(ESI)C16H17NO3[M+Na]+:理论值:294.1101,实测值:294.1091。
实施例18合成N-(3-羟基-5-苯氧基苯基)-苯甲酰胺
Figure BDA0001502931470000172
在100mL圆底烧瓶中,加入1-溴-3-甲氧基硝基苯(4.64g,20mmol)、铁粉(5.6g,100mmol)、醋酸/甲醇/水混合溶剂20mL,在反应液中加入一滴浓盐酸,在109℃反应1h,然后在室温下反应4h。在反应液中加入20mL水,用乙酸乙酯(20mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶层析纯化(石油醚/乙酸乙酯梯度洗脱),得到黄色固体即3-溴-5-甲氧基苯胺2.15g,产率54%。
在100mL圆底烧瓶中,在冰浴冷却下加入3-溴-5-甲氧基苯胺(301mg,1.5mmol)、苯甲酰氯(190μL,1.65mmol)、三乙胺(228μL,1.65mmol)和重蒸的四氢呋喃15mL,在室温下反应12h。在反应液中加入15mL水,用乙酸乙酯(20mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶层析纯化(石油醚/乙酸乙酯梯度洗脱),得到白色固体N-(3-溴-5-甲氧基苯基)苯甲酰胺256mg,产率55%。
在100mL两口瓶中,加入苯酚(112mg,1.2mmol)、N-(3-溴-5-甲氧基苯)苯甲酰胺(244mg,0.8mmol)、磷酸钾(339mg,1.6mmol)、碘化亚铜(15mg)和无水DMSO15mL,在氩气保护下于110℃反应过夜。反应液冷却后加入15mL水,用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂,残余物用硅胶层析纯化(石油醚/乙酸乙酯梯度洗脱)得到N-(3-甲氧基-5-苯氧基苯)苯甲酰胺140mg,产率55%。
在100mL圆底烧瓶中,加入N-(3-甲氧基-5-苯氧基苯基)苯甲酰胺(140mg,0.44mmol)和重蒸的二氯甲烷10mL,在-78℃下缓慢滴加三溴化硼二氯甲烷溶液2.2mL(1mol/L),加完后在0℃下继续反应12h。反应液用饱和碳酸氢钠淬灭,然后用二氯甲烷(20mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶层析纯化(石油醚/乙酸乙酯梯度洗脱),得到黄色固体即N-(3-羟基-5-苯氧基苯基)-苯甲酰胺53mg,产率40%。
1H NMR(400MHz,DMSO)δ10.16(s,1H),9.67(d,J=22.8Hz,1H),7.93(d,J=7.2Hz,2H),7.59(t,J=7.2Hz,1H),7.52(t,J=7.3Hz,2H),7.46–7.37(m,2H),7.22(s,1H),7.17(t,J=7.4Hz,1H),7.08(d,J=7.8Hz,2H),6.98(m,1H).13C NMR(100MHz,DMSO)δ166.10,159.17,158.35,156.89,141.62,135.45,131.99,130.43,128.78,128.12,123.99,119.55,102.94,101.68,101.58.高分辨质谱(ESI)C19H15NO3[M+H]+:理论值:306.1125,实测值:306.1113。
实施例19合成N-(3-羟基-5-苯胺基苯基)-苯甲酰胺
Figure BDA0001502931470000191
N-(3-溴-5-甲氧基苯基)-苯甲酰胺的合成参见实施例18。在100mL两口瓶中,加入苯胺(110μL,1.2mmol)、N-(3-溴-5-甲氧基苯)苯甲酰胺(244mg,0.8mmol)、磷酸钾(339mg,1.6mmol)、碘化亚铜(15mg)和无水DMSO 15mL,在氩气保护下于110℃反应过夜。反应液冷却后加入15mL水,用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂,残余物用硅胶层析纯化(石油醚/乙酸乙酯梯度洗脱)得到N-(3-甲氧基-5-苯胺基苯基)-苯甲酰胺152mg,产率60%。
在100mL圆底烧瓶中,加入N-(3-甲氧基-5-苯胺基苯基)-苯甲酰胺(152mg,0.48mmol)和重蒸的二氯甲烷10mL,在-78℃下缓慢滴加三溴化硼二氯甲烷溶液2.4mL(1mol/L),加完后在0℃下继续反应12h。反应液用饱和碳酸氢钠淬灭,然后用二氯甲烷(20mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶层析纯化(石油醚/乙酸乙酯梯度洗脱)得到白色固体即N-(3-羟基-5-苯胺基苯基)-苯甲酰胺75mg,产率53%。
1H NMR(400MHz,CDCl3)δ9.98(s,1H),9.21(s,1H),8.05(s,1H),7.95–7.87(m,2H),7.60–7.54(m,1H),7.54–7.47(m,2H),7.27–7.17(m,2H),7.09(m,3H),6.86–6.78(m,2H),6.25(t,J=2.0Hz,1H).13C NMR(101MHz,DMSO)δ165.89,158.55,144.89,143.90,141.05,135.73,131.82,129.49,128.74,128.10,120.01,117.69,100.34,100.18,99.98.高分辨质谱(ESI)C19H16N2O2[M+H]+:理论值:305.1285,实测值:305.1279。
实施例20合成N-(3-羟基-5-(甲基苯胺基)苯基)-苯甲酰胺
Figure BDA0001502931470000201
N-(3-溴-5-甲氧基苯基)-苯甲酰胺的合成参见实施例18。在100mL两口瓶中,加入N-甲基苯胺(130μL,1.2mmol)、N-(3-溴-5-甲氧基苯基)苯甲酰胺(244mg,0.8mmol)、磷酸钾(339mg,1.6mmol)、碘化亚铜(15mg)和无水DMSO 15mL,在氩气保护下于110℃反应过夜。反应液冷却后加入15mL水,用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂,残余物用硅胶层析纯化(石油醚/乙酸乙酯梯度洗脱)得到N-(3-甲氧基-5-(甲基苯胺基)苯基)-苯甲酰胺127mg,产率52%。
在100mL圆底烧瓶中,加入N-(3-甲氧基-5-(甲基苯胺基)苯基)-苯甲酰胺(152mg,0.48mmol)和重蒸的二氯甲烷10mL,在-78℃下缓慢滴加三溴化硼二氯甲烷溶液2.4mL(1mol/L),加完后在0℃下继续反应12h。反应液用饱和碳酸氢钠淬灭,然后用二氯甲烷(20mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶层析纯化(石油醚/乙酸乙酯梯度洗脱)得到白色固体即N-(3-羟基-5-(甲基苯胺基)苯基)-苯甲酰胺67mg,产率55%。
1H NMR(400MHz,DMSO)δ10.08(s,1H),9.36(s,1H),7.97(dd,J=21.2,7.8Hz,2H),7.61(t,J=7.2Hz,1H),7.54(t,J=7.4Hz,2H),7.34(t,J=7.5Hz,2H),7.09(d,J=8.2Hz,3H),7.00(t,J=7.2Hz,1H),6.95(s,1H),6.19(s,1H),6.19(s,1H),3.26(s,3H).13C NMR(101MHz,DMSO)δ165.88,158.54,150.16,149.11,141.11,135.60,131.86,129.62,128.74,128.08,121.88,121.44,103.38,102.89,101.30,40.56.高分辨质谱(ESI)C20H18N2O2[M+Na]+:理论值:341.1260,实测值:341.1240。
实施例21合成N-(3-羟基-5-(甲基-2-吡啶基胺基)苯基)-苯甲酰胺
Figure BDA0001502931470000211
N-(3-溴-5-甲氧基苯基)-苯甲酰胺的合成参见实施例18。在100mL两口瓶中,加入2-甲胺基吡啶(123μL,1.2mmol)、N-(3-溴-5-甲氧基苯基)-苯甲酰胺(244mg,0.8mmol)、磷酸钾(339mg,1.6mmol)、碘化亚铜(15mg)和无水DMSO 15mL,在氩气保护下于110℃反应过夜。反应液冷却后加入15mL水,用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂,残余物用硅胶层析纯化(石油醚/乙酸乙酯梯度洗脱)得到N-(3-甲氧基-5-(甲基-2-吡啶基胺基)苯基)-苯甲酰胺117mg,产率48%。
在100mL圆底烧瓶中,加入N-(3-甲氧基-5-(甲基-2-吡啶基胺基)苯基)-苯甲酰胺(152mg,0.48mmol)和重蒸的二氯甲烷10mL,在-78℃下缓慢滴加三溴化硼二氯甲烷溶液2.4mL(1mol/L),加完后在0℃下继续反应12h。反应液用饱和碳酸氢钠淬灭,然后用二氯甲烷(20mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶层析纯化(石油醚/乙酸乙酯梯度洗脱)得到白色固体即N-(3-羟基-5-(甲基-2-吡啶基胺基)苯基)-苯甲酰胺64mg,产率57%。
1H NMR(400MHz,DMSO)δ10.14(s,1H),9.59(s,1H),8.16(dd,J=5.0,1.1Hz,1H),7.95–7.89(m,2H),7.58(dd,J=8.4,6.1Hz,1H),7.51(t,J=7.3Hz,2H),7.45(t,J=6.9Hz,1H),7.26(t,J=1.9Hz,1H),7.17(s,1H),6.70–6.65(m,1H),6.63(d,J=8.6Hz,1H),6.41(t,J=2.0Hz,1H),3.35(s,3H).13C NMR(101MHz,DMSO)δ166.02,158.95,158.62,148.03,147.80,141.51,137.31,135.43,132.03,128.82,128.12,113.77,109.70,108.77,108.46,104.94,38.41.高分辨质谱(ESI)C19H17N3O2[M+H]+:理论值:320.1394,实测值:320.1373。
实施例22合成N-(3-羟基-5-(甲基-2-吡嗪基胺基)苯基)-苯甲酰胺
Figure BDA0001502931470000221
N-(3-溴-5-甲氧基苯基)-苯甲酰胺的合成参见实施例18。在100mL两口瓶中,加入2-甲胺基吡嗪(114μL,1.2mmol)、N-(3-溴-5-甲氧基苯基)-苯甲酰胺(244mg,0.8mmol)、磷酸钾(339mg,1.6mmol)、碘化亚铜(15mg)和无水DMSO 15mL,在氩气保护下于110℃反应过夜。反应液冷却后加入15mL水,用乙酸乙酯(15mL×2)萃取,萃取液在减压下除去溶剂,残余物用硅胶层析纯化(石油醚/乙酸乙酯梯度洗脱)得到N-(3-甲氧基-5-(甲基-2-吡嗪基胺基)苯基)-苯甲酰胺122mg,产率50%。
在100mL圆底烧瓶中,加入N-(3-甲氧基-5-(甲基-2-吡嗪基胺基)苯基)-苯甲酰胺(152mg,0.48mmol)和重蒸的二氯甲烷10mL,在-78℃下缓慢滴加三溴化硼二氯甲烷溶液2.4mL(1mol/L),加完后在0℃下继续反应12h。反应液用饱和碳酸氢钠淬灭,然后用二氯甲烷(20mL×2)萃取,萃取液在减压下除去溶剂得到粗产物,用硅胶层析纯化(石油醚/乙酸乙酯梯度洗脱)得到白色固体即N-(3-羟基-5-(甲基-2-吡嗪基胺基)苯基)-苯甲酰胺62mg,产率53%。
1H NMR(400MHz,DMSO)δ10.21(s,1H),9.73(s,1H),8.15(s,1H),8.01(s,1H),7.92(d,J=7.7Hz,2H),7.87(s,1H),7.58(t,J=7.0Hz,1H),7.52(t,J=7.3Hz,2H),7.32(s,1H),7.22(s,1H),6.47(s,1H),3.36(s,3H).13C NMR(101MHz,DMSO)δ166.07,159.23,154.66,146.24,141.97,141.72,135.35,133.17,133.03,132.05,128.82,128.11,108.72,108.47,105.74,38.21.高分辨质谱(ESI)C18H16N4O2[M+H]+:理论值:321.1346,实测值:321.1331。
上述实施例制得的间二取代苯酚化合物的结构式和编号整理如表1:
表1实施例制得的代表性间二取代苯酚化合物
Figure BDA0001502931470000231
Figure BDA0001502931470000241
Figure BDA0001502931470000251
效果实施例实施例化合物的抗结核活性测定
1.平板法测定实施例化合物对结核分枝杆菌的最低抑菌浓度(MIC)
(1)结核分枝杆菌标准株H37Rv(广州市胸科医院提供)的液体培养:在7H9培养基(购买于Difco公司)中培养,37℃摇床长培养至菌液600nm下吸光值(OD600)为0.3~0.7,得到结核菌H37Rv培养液。
(2)配制不同浓度待测化合物的7H11培养基(购买于Difco公司)平板:将待测化合物用DMSO溶解,配制成适当浓度的初溶液,用7H11培养基进行稀释,每种化合物各10个浓度梯度,在96孔板中每孔加入100μL,待测化合物的终浓度分别为10,5,2.5,1.25,0.625,0.312,0.15,0.075,0.0375,0.019μg/mL。
(3)每孔接种100μL结核菌H37Rv培养液,每板均设有抗菌药异烟肼的阳性对照孔和不含有测试药物的DMSO替代阴性对照孔,将96孔板加盖后置于37℃培养。第三天后观察每孔中结核菌的生长情况并记录结果,第七天后再观察记录一次进行确认。分析数据,得出各化合物对于结核分枝杆菌H37Rv生长的最低抑制浓度(MIC),结果如下表2。
表2实施例化合物对结核分枝杆菌H37Rv的最低抑制浓度(MIC)
Figure BDA0001502931470000252
Figure BDA0001502931470000261
由表2结果可知,实施例化合物对结核菌H37Rv的生长具有很强的抑制作用,其中化合物2、3、7、15的MIC值分别达到0.625μg/mL、0.312μg/mL、1.25μg/mL、0.625μg/mL。
2.实施例化合物对临床分离的多药耐药结核菌株的最低抑制浓度(MIC)
P103、R7和P91为从广州市胸科医院临床分离的耐药结核分支杆菌株,所述的菌株对于常用的抗结核药物异烟肼和利福平耐药。
表3实施例化合物对多药耐药结核菌株的最低抑制浓度MIC
Figure BDA0001502931470000262
a H表示异烟肼;R表示利福平
由表3可知,化合物2和化合物3对于上述多药耐药结核菌株的生长也具有很强的抑制作用。
对比例
以下通过对比实施例说明本发明的间二取代苯酚化合物的结构特殊性与其抗结核菌活性密切相关,破坏该结构特殊性将导致得到的化合物完全或者很大程度上丧失抗结核菌活性。化合物6对于结核菌H37RV具有强的抑制活性(MIC=5μg/mL),然而去掉苯甲酰胺基,或者去掉3位苄基,或者将5位羟基甲基化,或者用羧基替换5位羟基,或者3位苄基氧化后得到的相应化合物都基本丧失了对于结核菌H37RV的生长抑制活性,这些对比结果充分说明了本发明的间二取代苯酚化合物的结构特殊性是其具备抗结核活性的关键。
化合物6
Figure BDA0001502931470000271
对比化合物
Figure BDA0001502931470000272
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。

Claims (9)

1.一类通式为(Ⅰ)的间二取代苯酚化合物或其药学可接受的盐,
Figure FDA0002269077680000011
其中,R1为甲基、乙基、乙烯基、C3~C8烷基及环烷基、甲氧基、苯基、萘基、噻吩基、呋喃基、吡啶基、嘧啶基、喹啉基、噻唑基、噻二唑基、苯氧基、苄氧基、乙氧基、C3~C8烷基氧基及环烷基氧基、四氢吡喃基、四氢呋喃基;或在芳香环上有单取代或者多取代基的苯基、萘基、噻吩基、呋喃基、吡啶基、嘧啶基、喹啉基、噻唑基、苯氧基、苄氧基,所述的取代基为甲基、乙基、C3~C6烷基及环烷基、氟、氯、溴、甲氧基、硝基、三氟甲基、腈基、羟基中的至少一种;
R2为无取代、单取代或多取代的苯基、噻吩基、呋喃基、吡啶基、吡嗪基、嘧啶基、噻唑基、吡唑基、三氮唑基,所述的取代基为甲基、氟、氯、溴、甲氧基、三氟甲基、腈基中的至少一种;
X为CH2、O、NH和NCH3
所述的间二取代苯酚化合物不包含如下结构的化合物:
Figure FDA0002269077680000012
2.根据权利要求1所述的通式为(Ⅰ)的间二取代苯酚化合物或其药学可接受的盐,其特征在于:
所述的R1为C5~C8环烷基、苯基、苯基氧基、C5~C8环烷基氧基;或在苯环上有单取代或者多取代的苯基、苯基氧基,所述的取代基为甲基、氯、氟中的至少一种。
3.根据权利要求1所述的通式为(Ⅰ)的间二取代苯酚化合物或其药学可接受的盐,其特征在于:
所述的R2为苯基。
4.根据权利要求1所述的通式为(Ⅰ)的间二取代苯酚化合物或其药学可接受的盐,其特征在于:
所述的X为CH2或NCH3
5.根据权利要求1所述的通式为(Ⅰ)的间二取代苯酚化合物或其药学可接受的盐,其特征在于,所述的间二取代苯酚化合物选自如下化合物之一:
3-苄基-5-羟基苯基-氨基甲酸-4,4-二甲基环己酯;
N-(3-苄基-5-羟基苯基)-4,4-二甲基-环己烷甲酰胺;
N-(3-苄基-5-羟基苯基)-4-甲基苯甲酰胺;
N-(3-羟基-5-(甲基苯胺基)苯基)-环己烷甲酰胺;
N-(3-苄基-5-羟基苯基)环己基甲酰胺;
N-(3-苄基-5-羟基苯基)-2-(4,4-二甲基环己基)乙酰胺;
N-(3-苄基-5-羟基苯基)苯甲酰胺;
N-(3-苄基-5-羟基苯基)-2-氯苯甲酰胺;
N-(3-苄基-5-羟基苯基)-2,4-二氯苯甲酰胺;
N-(3-苄基-5-羟基苯基)-2-氯烟酰胺;
N-(3-苄基-5-羟基苯基)噻吩-2-甲酰胺;
3-苄基-5-羟基苯基-氨基甲酸乙酯;
N-(3-羟基-5-苯氧基苯基)-苯甲酰胺;
N-(3-羟基-5-(甲基苯胺基)苯基)-苯甲酰胺;
N-(3-羟基-5-(甲基-2-吡啶基胺基)苯基)-苯甲酰胺;
N-(3-羟基-5-(甲基-2-吡嗪基胺基)苯基)-苯甲酰胺;
N-(3-苄基-5-羟基苯基)-2-苯乙酰胺;
N-(3-苄基-5-羟基苯基)-4,4-二氟环己基甲酰胺;
N-(3-苄基-5-羟基苯基)四氢吡喃-4-甲酰胺。
6.一种药物组合物,其特征在于:
包括权利要求1~5任一项所述的间二取代苯酚化合物或其药学可接受的盐,以及任选的药学可接受的辅料、载体或赋形剂。
7.权利要求1~5任一项所述的间二取代苯酚化合物的制备方法,其特征在于,
当X为CH2时,包括如下步骤:采用3-硝基-5-甲氧基苯甲酸为原料,经过还原成醇、傅克烷基化、脱甲基、硝基还原和酰化反应制备得到所述的间二取代苯酚化合物;
或者,
当X为O、NH、NCH3时,包括如下步骤:采用3-溴-5-硝基苯甲醚为原料,经过硝基还原、酰化、偶联、脱甲基反应制备得到所述的间二取代苯酚化合物。
8.权利要求1~5任一项所述的间二取代苯酚化合物或其药学可接受的盐或权利要求6所述的药物组合物的应用,其特征在于:
在制备预防和/或治疗结核病的药物中的应用。
9.权利要求1~5任一项所述的间二取代苯酚化合物或其药学可接受的盐或权利要求6所述的药物组合物的应用,其特征在于:
所述的应用为在制备预防和/或治疗结核分枝杆菌感染引起的疾病的药物中的应用。
CN201711310722.7A 2017-12-11 2017-12-11 间二取代苯酚化合物及其制备方法与抗结核菌应用 Expired - Fee Related CN107973727B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711310722.7A CN107973727B (zh) 2017-12-11 2017-12-11 间二取代苯酚化合物及其制备方法与抗结核菌应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711310722.7A CN107973727B (zh) 2017-12-11 2017-12-11 间二取代苯酚化合物及其制备方法与抗结核菌应用

Publications (2)

Publication Number Publication Date
CN107973727A CN107973727A (zh) 2018-05-01
CN107973727B true CN107973727B (zh) 2020-04-17

Family

ID=62009978

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711310722.7A Expired - Fee Related CN107973727B (zh) 2017-12-11 2017-12-11 间二取代苯酚化合物及其制备方法与抗结核菌应用

Country Status (1)

Country Link
CN (1) CN107973727B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110563656A (zh) * 2018-06-06 2019-12-13 四川大学 嘧啶类小分子化合物及在制备抗分枝杆菌药物中的用途
CN112843027B (zh) * 2021-02-03 2022-08-09 中山大学 2-氯-6-甲氧基间苯二酚在抑制结核分枝杆菌酪氨酸磷酸酶a中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104873522A (zh) * 2014-02-28 2015-09-02 中国科学院广州生物医药与健康研究院 N-4-三氟甲基苯基水杨酰胺衍生物的制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR076880A1 (es) * 2009-05-18 2011-07-13 Orion Corp Inhibidores de proteasa, composiciones farmaceuticas que los contienen y su uso.
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104873522A (zh) * 2014-02-28 2015-09-02 中国科学院广州生物医药与健康研究院 N-4-三氟甲基苯基水杨酰胺衍生物的制备方法和应用

Also Published As

Publication number Publication date
CN107973727A (zh) 2018-05-01

Similar Documents

Publication Publication Date Title
JP4919810B2 (ja) マイコバクテリア抑制剤としての使用のためのキノリン誘導体
EP2262769B1 (fr) Derives de 2-aryl-6-phenyl-imidazo[1,2-a]pyridines polysubstitues, leur préparation et leur application en thérapeutique
US20120059026A1 (en) Antimicrobial agents
CN107973727B (zh) 间二取代苯酚化合物及其制备方法与抗结核菌应用
FR2928921A1 (fr) Derives polysubstitues de 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, leur preparation et leur application en therapeutique
JPH06504534A (ja) キサンチン誘導体
JP6905506B2 (ja) ピペリジン誘導体
EP4180429A1 (en) Pyrimidinone derivative, and preparation method therefor and use thereof against mycobacterium tuberculosis infection
KR20110093928A (ko) 아릴알킬카르바메이트 유도체, 그의 제조 방법 및 치료학에서의 그의 용도
JPS6344572A (ja) 抗不整脈剤
US20140350024A1 (en) Antimicrobial agents
EP0162975B1 (en) P-alkyl or cycloalkyl phenoxy alkanols and alkanol esters and use for the treatment of allergic conditions
CA2289100A1 (en) Quinoline derivatives as pde iv and/or tnf inhibitors
JP6824898B2 (ja) 5−オキソ−ete受容体アンタゴニストとしてのインドール類似体及びその使用方法
EP2477990B1 (fr) Dérivés de 5-phenyl-pyrazolopyridine, leur préparation et leur application en thérapeutique
JPH0374370A (ja) ピラジン誘導体およびこれを含有する血小板凝集抑制剤または抗炎症剤
HUT71556A (en) Cyclooxygenase and 5-lipoxygenase inhibiting n(3-biphenylyl-1(s)-methyl-2-propenyl) acetohydroxamic acid derivatives, pharmaceutical compns. contg. them and process to prepare the said compds.
JPH02292213A (ja) 制癌剤
EP2487157A1 (en) Enantioselective synthesis method of 4-aminoalcoholquinoline derivatives and the use
CA2526637A1 (en) Carboxylic acid compound and medecine comprising the same
EP2477988B1 (fr) Dérivés acétyléniques de 5-phényl-pyrazolopyridine, leur préparation et leur application en thérapeutique
US20190276478A1 (en) Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections
WO2023230002A1 (en) Nlrp3 inflammasome inhibitors
BR102021026090A2 (pt) Derivados selenoetilenolacticamidas para um medicamento no tratamento da tuberculose
JPH0567141B2 (zh)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200417